Physician profile
David L Edelman
NPI 1366482960
$2,414.71
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $221 · 2021: $251 · 2022: $604 · 2023: $632 · 2024: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $875.64 | 2019-2024 | |
| Biogen, INC. | $455.23 | 2019-2023 | Vumerity, Tysabri |
| Ucb, INC. | $295.65 | 2019-2024 | Rystiggo |
| Abbvie INC. | $150.98 | 2021-2023 | Ubrelvy, Qulipta |
| Sunovion Pharmaceuticals INC. | $147.66 | 2019-2021 | |
| Emd Serono, INC. | $75.41 | 2020-2021 | |
| Celgene Corporation | $65.90 | 2023 | Zeposia |
| Allergan, INC. | $65.27 | 2020 | |
| Alexion Pharmaceuticals, INC. | $47.27 | 2023-2024 | Ultomiris |
| Pfizer INC. | $41.29 | 2023 | |
| Sk Life Science, INC. | $36.26 | 2020 | |
| Lilly USA, LLC | $34.39 | 2022-2023 | Amyvid |
| Avanir Pharmaceuticals, INC. | $32.96 | 2019 | |
| Supernus Pharmaceuticals, INC. | $28.04 | 2020 | |
| Eisai INC. | $24.74 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $13.50 | 2024 | Nuedexta |
| Bolder Surgical LLC | $13.13 | 2019 | |
| Amgen INC. | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Edelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.